# Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

> **NCT01044329** · PHASE2 · UNKNOWN · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 90 (estimated)

## Conditions studied

- Branch Retinal Vein Occlusion

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Triamcinolone Acetonide

## Key facts

- **NCT ID:** NCT01044329
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2010-08
- **Final completion:** 2010-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2010-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01044329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01044329, "Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01044329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*